PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Infectious Diseases, Mayo Clinic, Rochester, MN. Electronic address: Temesgen.zelalem@mayo.edu.\', \'Division of Infectious Diseases, Mayo Clinic, Rochester, MN.\', \'Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.\', \'Department of Anesthesia and Critical Care Medicine, Mayo Clinic, Rochester, MN.\', \'Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL.\', \'Division of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL.\', \'Division of Infectious Diseases, Mayo Clinic, Scottsdale, AZ.\', \'Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ.\', \'Humanigen, Inc, Burlingame, CA.\', \'T Cell Engineering, Mayo Clinic, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN.\', \'T Cell Engineering, Mayo Clinic, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN; Department of Immunology, Mayo Clinic, Rochester, MN; Department of Molecular Medicine, Mayo Clinic, Rochester, MN.\', \'Division of Infectious Diseases, Mayo Clinic, Rochester, MN; Department of Molecular Medicine, Mayo Clinic, Rochester, MN.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0025-6196(20)30989-710.1016/j.mayocp.2020.08.038
?:doi
?:hasPublicationType
?:journal
  • Mayo Clinic proceedings
is ?:pmid of
?:pmid
?:pmid
  • 33153629
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.551
?:rankingScore_hIndex
  • 153
is ?:relation_isRelatedTo_publication of
?:title
  • GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all